Functional Genetics, Inc. (FGI) is a development-stage biotechnology company that uses innovative science to develop new therapeutics for infectious disease. Our novel antiviral products address widespread and intractable diseases that have persistently inflicted considerable suffering and death. Our products facilitate simultaneous targeting of multiple co-morbid pathogens with a single drug. Examples include targeting of distinct respiratory viruses (RSV, PIV, influenza), hepatitis viruses (HBV, HCV), sexually-transmitted diseases (HIV, Herpes) or biothreat (Ebola, Marburg) agents. Our new antiviral drugs (small molecule and monoclonal antibodies) are crafted to be broad-spectrum in application and durable in response. Based on our approach, we minimize the potential for the outgrowth of drug-resistant viruses. Our first IND is scheduled for 2009 with two additional INDs for different products to be filed in 2010. The Company was originally formed to advance a novel technology to discover novel targets and pathways. This RHGP technology can interrogate the entire genome to identify causative events for new target discovery. FGI and its collaborators have successfully utilized RHGP to identify novel targets for oncology, infectious disease, cardiovascular disease, Alzheimer's disease and enhanced production of biologics-based therapeutics.